InsidersTradesSigma
Follow the Nuvalent, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Nuvalent, Inc. has logged 313 public disclosures. Market capitalisation: €9.8bn. The latest transaction was reported on 17 July 2026 (U). Among the most active insiders: Balcom Alexandra. Every trade is accessible without an account.
313
Insider Decl.
n/a
Thresholds
€27m
2 ops.
Buy Volume
€2bn
98 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Nuvalent, Inc. Hold (neutral), based on 9 analysts. Average price target: US$124.00.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 July 2026
Declarations313 total
5,146 shares@ US$124.000.0065% mcap0.0% of flowClass A Common StockSEC:0001193805-26-000978:3
3,444 shares@ US$124.000.0044% mcap0.0% of flowClass A Common Stock - Restricted Stock UnitsSEC:0001193805-26-000978:5
5,146 shares@ US$124.000.0065% mcap0.0% of flowClass A Common StockSEC:0001193805-26-000978:4
8,299,225 shares@ US$124.0010.52% mcap44.7% of flowClass A Common StockSEC:0001193805-26-000978:0
8,299,225 shares@ US$124.0010.52% mcap44.7% of flowClass A Common StockSEC:0001193805-26-000978:1
650,000 shares@ US$124.000.82% mcap3.5% of flowClass A Common StockSEC:0001193805-26-000978:2
14,350 sharesClass A Common Stock - Performance Stock UnitsSEC:0001193125-26-305094:3
3,444 sharesClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305052:1
22,393 shares@ US$124.000.028% mcap53.9% of flowClass A Common StockSEC:0001193125-26-305062:0
44,433 shares@ US$124.000.056% mcap38.8% of flowClass A Common StockSEC:0001193125-26-305094:0
41,100 sharesClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305094:1
14,350 shares0Class A Common Stock - Performance Stock UnitsSEC:0001193125-26-305094:2
3,714 shares@ US$124.000.0047% mcap100.0% of flowClass A Common StockSEC:0001193125-26-305051:0
5,577 sharesClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305051:1
21,092 shares@ US$124.000.027% mcap100.0% of flowClass A Common StockSEC:0001193125-26-305068:0
29,433 sharesClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305068:1
7,120 sharesClass A Common Stock - Performance Stock UnitsSEC:0001193125-26-305068:3
5,146 shares@ US$124.000.0065% mcap100.0% of flowClass A Common StockSEC:0001193125-26-305095:0
3,444 sharesClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305095:1
18,534 shares@ US$124.000.024% mcap39.8% of flowClass A Common StockSEC:0001193125-26-305058:0
41,100 sharesClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305058:1
14,350 sharesClass A Common Stock - Performance Stock UnitsSEC:0001193125-26-305058:3
17,017 shares@ US$124.000.022% mcap22.4% of flowClass A Common StockSEC:0001193125-26-305072:0
41,100 sharesClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305072:1
14,350 sharesClass A Common Stock - Performance Stock UnitsSEC:0001193125-26-305072:3
25 of 313 declarations
关于 Nuvalent, Inc.
Nuvalent, Inc. 是一家总部位于美国的生物制药公司，在纳斯达克上市，股票代码为 NUVL。公司总部位于马萨诸塞州剑桥，专注于精准肿瘤学，更具体地说，专注于开发针对非小细胞肺癌 (NSCLC) 基因定义亚群的高度选择性激酶抑制剂。该公司成立于 2020 年代初期，其战略围绕一个相对狭窄但科学要求高的论点：设计小分子，通过解决耐药性、限制脱靶毒性和更好地穿透中枢神经系统来改进现有靶向疗法。（[investors.nuvalent.com](https://investors.nuvalent.com/2026-04-07-Nuvalent-Announces-Submission-of-New-Drug-Application-to-FDA-for-Neladalkib-in-TKI-Pre-treated-Advanced-ALK-positive-NSCLC?utm_source=openai)） 其核心产品线围绕三个主要项目：zidesamtinib (NVL-520)，一种 ROS1 选择性抑制剂；neladalkib (NVL-655)，一种 ALK 选择性抑制剂；以及 NVL-330，一种 HER2 选择性抑制剂。该公司还有多个处于发现阶段的研究项目。从投资者的角度来看，这使得 Nuvalent 成为一个专注于肿瘤学的平台，而不是一个多元化的制药企业。其竞争优势基于结构引导设计和异常高的靶点选择性，旨在为对先前激酶抑制剂产生耐药性或需要具有更好耐受性和更持久反应的疗法患者提供服务。（[investors.nuvalent.com](https://investors.nuvalent.com/overview?utm_source=openai)） Nuvalent 的地理足迹集中在美国，其公司基地、临床运营和投资者关系职能均设于此，尽管其试验和开发项目具有全球范围。该公司最近的新闻流一直非常积极。2026 年 4 月 7 日，Nuvalent 宣布向美国 FDA 提交 neladalkib 治疗经 TKI 预处理的晚期 ALK 阳性 NSCLC 的新药申请 (NDA)，该申请得到了 ALKOVE-1 1/2 期试验数据的支持。2026 年 5 月，该公司还表示 zidesamtinib 正在接受 FDA 审查，并有一个 PDUFA 目标日期，这表明至少有两个主要项目已进入后期监管拐点。此外，Nuvalent 的投资者材料强调了持续的产品线势头和多个预期里程碑，这对于评估临床和监管执行风险至关重要。（[investors.nuvalent.com](https://investors.nuvalent.com/2026-04-07-Nuvalent-Announces-Submission-of-New-Drug-Application-to-FDA-for-Neladalkib-in-TKI-Pre-treated-Advanced-ALK-positive-NSCLC?utm_source=openai)）
